Venture Capital

With backing from Shaquille O'Neal and a solid business plan, the UPSHOT League tips off May 15, aiming to reshape the landscape of women's pro basketball.

Scooter giant Lime files for a landmark IPO, but its S-1 reveals massive debt, setting up a crucial test for the future of urban transport.

At a top Paris expo, GUYU's biotech arm BioQ unveiled cellular anti-aging ingredients, signaling a new era of Chinese innovation in the beauty supply chain.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

A three-month FDA delay for a new LEQEMBI injection highlights the high-stakes race for a convenient Alzheimer's therapy and its complex safety hurdles.

A KIST-led delegation of Korean quantum startups partners with IBM, signaling a major push to commercialize deep tech on the global stage.

A Swedish startup is launching a 'participation-first' video app in Brazil, betting that users are tired of passive scrolling. Can it succeed?

Faraday Future and a new business school are launching an ambitious robotics institute, but can they deliver on the promise to standardize the future of AI?

JingAn Kerry Centre's 'Axis for Sparks' season blends global brands like MONOCLE with ancient arts, fueling Shanghai's ambitious urban renaissance.

The media giant posted strong Q3 results, driven by a bold strategy to monetize its content with AI partners while aggressively suing content scrapers.

With a strong balance sheet and promising data, Enliven Therapeutics is pushing its lead leukemia drug, ELVN-001, into a pivotal late-stage trial.

As it nears $10B in assets, investment firm Disruptive hires a top tech advisor, signaling a new phase of strategic growth for its unique investment model.

Dr. David Rankey joins Wellvana as CMO, a strategic move as the company scales its model and the industry shifts from proof of concept to performance.

With its new CCO, the AI health-tech firm aims to commercialize its patient-data platform, tackling billion-dollar delays in drug development.

With new SAFE financing, Cubit Diagnostics advances its all-in-one molecular and immunoassay platform, aiming to revolutionize point-of-care STI testing.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.

Digital dentistry leader Medit acquires Progressive Orthodontics, launching a new division to merge high-tech scanning with world-class clinical training.

With $30M in new funding, Lunar Outpost is accelerating its robotic fleet to build the critical infrastructure for a permanent lunar economy and human presence.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

In just eight months, Propelis achieved full operational independence. Here’s how a strategic carve-out became a blueprint for speed and modernization.